4 minute read
Jan. 28, 2023
BI 685509: An sGC Activator for Kidney Diseases
BI 685509
oral sGC activator Ph. II for CDK & DKD discovery not disclosed J. Pharmacol. Exp. Ther., December 6, 2022 Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT
oral sGC activator Ph. II for CDK & DKD discovery not disclosed J. Pharmacol. Exp. Ther., December 6, 2022 Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT